CLOSE
MENU
Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
Jun 07, 2022
サブ-ナビゲーション
Company
Science/Pipleline
現在位置:
News
Investor Relations
Career
Contact
Privacy Policy
Term of use
Sitemap
Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
Jun 07, 2022
VIEW ALL
ページの先頭へ
ページの先頭へ
menu
gnavi-box